Varenicline decreases alcohol consumption in heavy-drinking smokers.
Varenicline decreases alcohol consumption in heavy-drinking smokers.
复制标题
DOI：
10.1007/s00213-012-2717-x
复制
发表时间：
2012-10
影响因子：
3.4
通讯作者：
Fields, Howard L.
中科院分区：
文献类型：
--
作者：
Mitchell, Jennifer M.;Teague, Candice H.;Kayser, Andrew S.;Bartlett, Selena E.;Fields, Howard L.
新的证据表明，烟碱乙酰胆碱受体 (nAChR) 的 α4β2 形式可调节酒精的奖赏效应。 nAChR α4β2 亚基部分激动剂伐尼克兰 (Chantix™) 经美国食品和药物管理局批准用于戒烟，也可减少啮齿类动物的乙醇消耗（Steensland 等人，Proc Natl Acad Sci U S A 104:12518–12523）以及人类实验室和开放标签研究（Fucito 等人，Psychopharmacology (Berl)） 215：655-663，；McKee 等人，《生物学精神病学》66：185-190）。我们提出了一项随机、双盲、为期 16 周的研究，对象是正在寻求吸烟治疗的重度饮酒吸烟者（随机接受治疗的 n = 64 名吸烟者）。该研究旨在确定伐尼克兰对酒精渴望和消费的影响。结果指标包括每周饮酒次数、每周吸烟量、每周对酒精的渴望量、治疗期间累计消耗的香烟和酒精饮料、戒酒天数以及每周乙基葡萄糖醛酸和可替宁筛查阳性的百分比。伐尼克兰显着降低吸烟者的饮酒量 (χ 2 = 35.32, p < 0.0001)。尽管伐尼克兰之前已被认为与自杀和抑郁有关，但本研究中的副作用较低，并且伐尼克兰治疗组的副作用随着时间的推移而下降。伐尼克兰可以使吸烟者的饮酒量持续减少。需要进一步的研究来评估伐尼克兰对寻求治疗但不吸烟的酗酒者的疗效，并确定伐尼克兰对吸烟和饮酒的影响之间的关系。
Emerging evidence suggests that the α4β2 form of the nicotinic acetylcholine receptor (nAChR) modulates the rewarding effects of alcohol. The nAChR α4β2 subunit partial agonist varenicline (Chantix™), which is approved by the Food and Drug Administration for smoking cessation, also decreases ethanol consumption in rodents (Steensland et al., Proc Natl Acad Sci U S A 104:12518–12523,) and in human laboratory and open-label studies (Fucito et al., Psychopharmacology (Berl) 215:655–663,; McKee et al., Biol Psychiatry 66:185–190). We present a randomized, double-blind, 16-week study in heavy-drinking smokers (n = 64 randomized to treatment) who were seeking treatment for their smoking. The study was designed to determine the effects of varenicline on alcohol craving and consumption. Outcome measures included number of alcoholic drinks per week, cigarettes per week, amount of alcohol craving per week, cumulative cigarettes and alcoholic drinks consumed during the treatment period, number of abstinent days, and weekly percentage of positive ethyl glucuronide and cotinine screens. Varenicline significantly decreases alcohol consumption (χ 2 = 35.32, p < 0.0001) in smokers. Although varenicline has previously been associated with suicidality and depression, side effects were low in this study and declined over time in the varenicline treatment group. Varenicline can produce a sustained decrease in alcohol consumption in individuals who also smoke. Further studies are warranted to assess varenicline efficacy in treatment-seeking alcohol abusers who do not smoke and to ascertain the relationship between varenicline effects on smoking and drinking.
登录
查看更多内容
DOI：
10.1523/jneurosci.2601-10.2010
发表时间：
2010-07-28
期刊：
The Journal of neuroscience : the official journal of the Society for Neuroscience
影响因子：
--
作者：
Hendrickson LM;Zhao-Shea R;Pang X;Gardner PD;Tapper AR
通讯作者：
Tapper AR
影响因子：
3.4
作者：
MELLO, NK;MENDELSON, JH;PALMIERI, SL
通讯作者：
PALMIERI, SL
DOI：
10.1073/pnas.0705368104
发表时间：
2007-07-24
影响因子：
11.1
作者：
Steensland, Pia;Simms, Jeffrey A.;Bartlett, Selena E.
通讯作者：
Bartlett, Selena E.
影响因子：
6.7
作者：
TOMASSON, K;VAGLUM, P
通讯作者：
VAGLUM, P
DOI：
10.1016/0899-3289(95)90008-x
发表时间：
1995-01-01
期刊：
Journal of substance abuse
影响因子：
--
作者：
Toneatto, A;Sobell, L C;Kozlowski, L T
通讯作者：
Kozlowski, L T